{"brief_title": "A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Dialysis Patients", "brief_summary": "This 6 month long study will assess an investigational medication for patients on dialysis with secondary hyperparathyroidism. The study will look at the effects on parathyroid hormone, calcium and phosphorus levels.", "condition": ["Secondary Hyperparathyroidism", "End Stage Renal Disease"], "intervention_type": ["Drug", "Drug"], "intervention_name": ["AMG 073", "Placebo"], "description": ["30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally", "30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally"], "arm_group_label": ["AMG 073", "placebo"], "criteria": "- Patients must be receiving hemodialysis; * Have elevated parathyroid hormone levels; * Not be pregnant or nursing; and * Not have had a heart attack in the last 3 months.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Neoplasm Metastasis", "Kidney Diseases", "Kidney Failure, Chronic", "Renal Insufficiency, Chronic", "Hyperparathyroidism", "Hyperparathyroidism, Secondary", "Cinacalcet Hydrochloride"], "id": "NCT00037635"}